Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Cardiac Insufficiency BIsoprolol Study in Japanese Patients with Chronic Heart Failure

Trial Profile

The Cardiac Insufficiency BIsoprolol Study in Japanese Patients with Chronic Heart Failure

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bisoprolol (Primary) ; Carvedilol (Primary)
  • Indications Chronic heart failure; Dilated cardiomyopathy; Ischaemic heart disorders
  • Focus Adverse reactions
  • Acronyms CIBIS-J
  • Most Recent Events

    • 06 Apr 2019 Primary endpoint (Tolerability: The probability that administered maintenance dose reaches the maximum (bisoprolol 5 mg/day, carvedilol 20 mg/day)) has not been met as per results published in the Circulation Journal.
    • 06 Apr 2019 Results published in the Circulation Journal
    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top